Meropenem

Where the papers sit

10 papers from the last 6 months study meropenem directly · updated from PubMed 28 Oct 2026

• Adjuvants Against Carbapenem Resistance

  Metallo-β-lactamase-producing Gram-negative bacteria are driving a shift from meropenem alone toward potentiated combinations. SKQ1 and zinc-binding ligands are being tested against NDM-1 and VIM-1, while clove-derived compounds target MRSA, Acinetobacter baumannii and other pathogens. Synergy is mainly judged by MIC, fractional inhibitory concentration indices and docking or binding analyses. Peptide nanoarchitectures broaden the strategy, but antibacterial activity and resistance restoration remain largely preclinical.

  4 papers · 40%

• Natural Biomaterials for Wound Care

  Plant-derived materials are being shaped into antimicrobial and wound-care platforms rather than evaluated as established therapies. Salvia officinalis-derived CoO nanoparticles are aimed at ESBL-producing bacteria, with activity supported by spectroscopy, microscopy and antioxidant assays. Aloe vera–Sterculia gum hydrogels emphasize wound healing and controlled drug delivery. The shared direction is formulation and materials optimization, while clinical effectiveness remains open.

  2 papers · 20%

• Others — Clinical Antibiotic Decision-Making

  Antibiotic decision-making spans kidney safety, sepsis trial design, dosing support and difficult meningitis cases. Vancomycin–piperacillin/tazobactam is repeatedly weighed against other β-lactams because of acute kidney injury, while meropenem versus piperacillin/tazobactam remains a feasibility question in critically ill sepsis. Large language models show inconsistent precision dosing for renal impairment. Pediatric Listeria meningitis adds indication-specific evidence, leaving no single clinical direction.

  4 papers · 40%